Genetic Technologies collaborations, innovation update

Genetic Technologies highlights a summary of the Company’s commitment to innovation. GTG’s global academic connections are exemplified by the Company’s collaboration. Some examples of these projects include but are not limited to: CASSOWARY project; BRCA 1/2 modifier project in breast cancer risk; GTG has provided letters of support as the lab service provider for future opportunities; Utility of Breast PRS in mammography; A range of internally funded research projects with US breast centres in New York, Miami and Houston to pilot the integrated risk assessment within an imaging facility.GTG’s CEO, Simon Morriss noted, “All of these important future initiatives highlight GTG’s ongoing commitment to continuous product improvement and new product development, underpinned by solid scientific validation and clinical utility. All the company’s risk assessment tests address areas of significant unmet medical need by assisting in stratifying people at elevated risk of disease and continuing to drive further adoption into the rapidly expanding area personalised medicine.”